Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis

Inflammation-induced decrease in voluntary wheel running in mice: A nonreflexive test for evaluating inflammatory pain and analgesia

“…The selective COX-2 inhibitor celecoxib showed lower efficacy than the non-selective COX inhibitors tested, which agrees with clinical studies showing a higher analgesic efficacy of ibuprofen over celecoxib [7,21]. The ED 50 of prednisolone was lower than that of the NSAIDs tested, which is also in agreement with the higher potency of this corticosteroid in reversing inflammation, and thereby inflammatory pain, in comparison to NSAIDs in short-term treatment [11] and shows the sensitivity of the test to anti-inflammatory drugs. Finally, morphine showed the highest potency of all the compounds tested, as expected [18,23,27,47] indicating that the test is suitable for testing analgesics.…”

Inflammation-induced decrease in voluntary wheel running in mice: A nonreflexive test for evaluating inflammatory pain and analgesia

“…The selective COX-2 inhibitor celecoxib showed lower efficacy than the non-selective COX inhibitors tested, which agrees with clinical studies showing a higher analgesic efficacy of ibuprofen over celecoxib [7,21]. The ED 50 of prednisolone was lower than that of the NSAIDs tested, which is also in agreement with the higher potency of this corticosteroid in reversing inflammation, and thereby inflammatory pain, in comparison to NSAIDs in short-term treatment [11] and shows the sensitivity of the test to anti-inflammatory drugs. Finally, morphine showed the highest potency of all the compounds tested, as expected [18,23,27,47] indicating that the test is suitable for testing analgesics.…”

A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs

“…The improvement seen with depomedrone, including reduction in the DAS, is less than that seen in trials in which new DMARDs are started, but is of a similar degree to that previously reported in systematic reviews of low dose oral steroids. 23 The notable exception is improvement in the HAQ score, which improved to a degree similar to that reported on starting treatment with sulfasalazine, methotrexate, and other DMARDs.…”

Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

“…Gotzsche and Johansen11 included 11 randomised trials that compared GCs at a maximum dose of 15 mg/day (in most of the studies, it was between 10 and 15 mg/day) with placebo or with a non-steroidal anti-inflammatory drug in patients with RA. These trials reported significantly better clinical outcomes in the GC-treated groups (SMD (95% CI): joint tenderness, SMD −1.16 (−1.69 to −0.64); pain, −1.51 (−2.31 to −0.71)) within 1 month of the start of therapy, supporting the concept of bridging.…”

Inflammation-induced decrease in voluntary wheel running in mice: A nonreflexive test for evaluating inflammatory pain and analgesia

“…The selective COX-2 inhibitor celecoxib showed lower efficacy than the non-selective COX inhibitors tested, which agrees with clinical studies showing a higher analgesic efficacy of ibuprofen over celecoxib [7,21]. The ED 50 of prednisolone was lower than that of the NSAIDs tested, which is also in agreement with the higher potency of this corticosteroid in reversing inflammation, and thereby inflammatory pain, in comparison to NSAIDs in short-term treatment [11] and shows the sensitivity of the test to anti-inflammatory drugs. Finally, morphine showed the highest potency of all the compounds tested, as expected [18,23,27,47] indicating that the test is suitable for testing analgesics.…”

A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs

“…The improvement seen with depomedrone, including reduction in the DAS, is less than that seen in trials in which new DMARDs are started, but is of a similar degree to that previously reported in systematic reviews of low dose oral steroids. 23 The notable exception is improvement in the HAQ score, which improved to a degree similar to that reported on starting treatment with sulfasalazine, methotrexate, and other DMARDs.…”

Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

“…Gotzsche and Johansen11 included 11 randomised trials that compared GCs at a maximum dose of 15 mg/day (in most of the studies, it was between 10 and 15 mg/day) with placebo or with a non-steroidal anti-inflammatory drug in patients with RA. These trials reported significantly better clinical outcomes in the GC-treated groups (SMD (95% CI): joint tenderness, SMD −1.16 (−1.69 to −0.64); pain, −1.51 (−2.31 to −0.71)) within 1 month of the start of therapy, supporting the concept of bridging.…”

Inflammation-induced decrease in voluntary wheel running in mice: A nonreflexive test for evaluating inflammatory pain and analgesia

“…The selective COX-2 inhibitor celecoxib showed lower efficacy than the non-selective COX inhibitors tested, which agrees with clinical studies showing a higher analgesic efficacy of ibuprofen over celecoxib [7,21]. The ED 50 of prednisolone was lower than that of the NSAIDs tested, which is also in agreement with the higher potency of this corticosteroid in reversing inflammation, and thereby inflammatory pain, in comparison to NSAIDs in short-term treatment [11] and shows the sensitivity of the test to anti-inflammatory drugs. Finally, morphine showed the highest potency of all the compounds tested, as expected [18,23,27,47] indicating that the test is suitable for testing analgesics.…”

A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs

“…The improvement seen with depomedrone, including reduction in the DAS, is less than that seen in trials in which new DMARDs are started, but is of a similar degree to that previously reported in systematic reviews of low dose oral steroids. 23 The notable exception is improvement in the HAQ score, which improved to a degree similar to that reported on starting treatment with sulfasalazine, methotrexate, and other DMARDs.…”

Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

“…Gotzsche and Johansen11 included 11 randomised trials that compared GCs at a maximum dose of 15 mg/day (in most of the studies, it was between 10 and 15 mg/day) with placebo or with a non-steroidal anti-inflammatory drug in patients with RA. These trials reported significantly better clinical outcomes in the GC-treated groups (SMD (95% CI): joint tenderness, SMD −1.16 (−1.69 to −0.64); pain, −1.51 (−2.31 to −0.71)) within 1 month of the start of therapy, supporting the concept of bridging.…”